Ipamorelin 10mg

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that has become a reference compound in growth hormone (GH) secretagogue research precisely because of what it doesn’t do. Developed by Novo Nordisk in the mid-1990s and first characterized in 1998, Ipamorelin was identified as the first GHRP-receptor agonist with a selectivity for GH release comparable to that of growth hormone-releasing hormone (GHRH) itself.

Where earlier secretagogues like GHRP-6 and GHRP-2 provoke measurable increases in ACTH, cortisol, and prolactin, Ipamorelin does not—even at doses more than 200-fold higher than its ED₅₀ for GH release. This “clean” endocrine signature is the defining feature of the molecule in the research literature.

This research-grade Ipamorelin is supplied as a sterile, lyophilized powder, independently verified by HPLC-UV (≥99% purity) and LC-MS identity confirmation, with a batch-specific Certificate of Analysis for full traceability.

Proposed mechanisms of interest in preclinical literature:

Selective GHS-R1a (ghrelin receptor) agonism: Ipamorelin binds the growth hormone secretagogue receptor 1a with a reported Ki of 63.4 nM and induces IP₃ accumulation in GHS-R1a-expressing cells (EC₅₀ = 46.9 nM), triggering a pulsatile release of GH from anterior pituitary somatotrophs. It mimics ghrelin’s action at the receptor without reproducing ghrelin’s broader metabolic effects.

GH release without ACTH/cortisol/prolactin spillover: In swine models, Ipamorelin released GH with an ED₅₀ of 2.3 nmol/kg while leaving FSH, LH, prolactin, and TSH unaffected. This selectivity makes it a cleaner tool for isolating GH-pathway effects in experimental design.

Downstream GH/IGF-1 signaling: By amplifying the endogenous GH pulse, Ipamorelin is studied for its potential to influence IGF-1 mediated pathways associated with lean mass retention, lipolysis, and connective-tissue remodeling. In rats, Ipamorelin (18–450 µg/animal) increased body weight and longitudinal bone growth.

Gastrointestinal motility: Ipamorelin has been shown to increase gastric emptying in a rat model of postoperative ileus at doses of 0.014 or 0.14 µmol/kg—an effect that has drawn interest beyond the performance-research context.

Synergy with GHRH analogs in research stacks: Ipamorelin is frequently investigated alongside CJC-1295 (a GHRH analog). The two act on distinct receptors—GHS-R1a and the GHRH receptor—and are studied for complementary, dual-pathway stimulation of GH release.

An important research context: Human pharmacology studies have confirmed that Ipamorelin produces a GH pulse after administration. However, no high-quality human randomized controlled trial has tested Ipamorelin against body composition, recovery, sleep, or aging endpoints specifically. The benefits most discussed in performance and longevity circles—lean mass, fat loss, deeper sleep, faster recovery—remain class-level extrapolations from GH/IGF-1 physiology, not demonstrated outcomes for Ipamorelin itself. A Phase II program in postoperative ileus was discontinued after failing to beat placebo on primary endpoints, underscoring the gap between mechanistic promise and clinical validation.

Product specifications:

Compound: Ipamorelin (NNC 26-0161)

Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂

CAS Number: 170851-70-4 (free base); 1258196-85-8 (acetate salt)

Molecular Formula: C₃₈H₄₉N₉O₅ (free base); C₃₈H₄₆N₅O₅·(C₂H₄O₂)₂ (diacetate)

Molecular Weight: 711.85 g/mol (free base); 831.96 g/mol (diacetate salt)

Appearance: White powder

Form: Lyophilized powder

Purity: ≥99% by HPLC-UV (batch-specific COA; representative lots test 99.4%+)

Identity Confirmation: LC-MS (mass spectrometry)

Acetate Content: <20.0% (HPLC, where applicable)

Peptide Content: ≥75.0% (N%)

Solubility: Soluble in bacteriostatic water, PBS, DMSO, ethanol

Storage (lyophilized): −20°C, desiccated, protected from light. Under these conditions, stability is measured in years. Exposure to moisture significantly degrades long-term stability.

Handling & reconstitution (research context):

Reconstitute with bacteriostatic water using aseptic technique. Inject the water slowly down the inner glass wall of the vial—do not spray directly onto the powder—then gently swirl or roll the vial. Do not shake or vortex; foaming indicates the air–liquid interface at which peptides can denature.

Once reconstituted, store refrigerated at 2–8°C and use within 2–4 weeks. Never freeze reconstituted Ipamorelin. Aliquot into single-use volumes to avoid repeated freeze–thaw cycles, which concentrate solutes and create fresh degradation interfaces.

Quick answers

How many protocol doses are in a 10mg vial?

At 100-300 mcg per pulse, a 10mg vial runs three to six weeks of once-to-twice-daily injections - the right sizing for a full secretagogue block rather than a taste. Fasting windows, the pre-bed timing trick and pulse logic live in the CJC-1295 + ipamorelin stack protocol.

Does ipamorelin really avoid cortisol and appetite spikes?

That is its entire selector advantage over older GHRPs - clean GH release without the prolactin, cortisol or ghrelin hunger tax. Which makes it the quiet first secretagogue, versus the oral convenience of MK-677 and its documented hunger.

Carbs before dosing?

Don't - meals and insulin blunt the pulse. Empty stomach, fasted window, or the 30-60 minute pre-bed slot. The pulse you paid for should not get cancelled by a sandwich.